Abbott Laboratories Q3 2026 Earnings: Beat on EPS Despite Revenue Miss
Abbott Laboratories (ABT) reported third-quarter 2026 earnings per share of $1.31, beating analyst estimates of $1.29 by 1.38%. However, the healthcare giant’s revenue of $12.59 billion fell short of the $12.62 billion consensus estimate by 0.23%, marking a mixed quarter for the diversified medical device and pharmaceutical company.
Abbott Laboratories operates across four primary business segments: medical devices, diagnostics, established pharmaceuticals, and nutrition products. The company is known for its FreeStyle glucose monitoring systems, heart devices including stents and pacemakers, COVID-19 testing solutions, and infant formula brands like Similac.
Earnings Performance Exceeds Expectations
The $1.31 EPS represents a solid performance against Wall Street’s $1.29 expectation, delivering a positive surprise of $0.02 per share. This marks Abbott’s ability to maintain profitability despite revenue headwinds. The earnings beat suggests effective cost management and operational efficiency improvements across the company’s diverse portfolio of healthcare products.
Compared to the same quarter in 2025, when Abbott reported EPS of $1.21, the current quarter shows an 8.3% year-over-year increase in earnings per share. This growth trajectory demonstrates the company’s continued ability to expand margins and drive bottom-line performance even in a challenging healthcare market environment.
Revenue Falls Short of Analyst Projections
Abbott’s $12.59 billion in quarterly revenue, while substantial, missed analyst expectations by approximately $29 million. The revenue figure represents a modest decline from the previous quarter’s $12.78 billion, indicating some softness in demand across certain business segments.
The medical devices segment, typically Abbott’s largest revenue contributor, faced headwinds from delayed elective procedures in certain markets. However, the diagnostics division showed resilience with continued demand for molecular testing solutions and point-of-care diagnostics. The nutrition segment experienced mixed performance, with international markets showing strength while domestic infant formula sales remained pressured by competitive dynamics.
Operational Metrics and Segment Performance
Abbott’s gross margin expanded to 58.2% in Q3 2026, up from 57.1% in the prior year period, reflecting improved manufacturing efficiency and favorable product mix. Operating margin reached 19.4%, compared to 18.7% in Q3 2025, demonstrating the company’s focus on operational excellence.
The FreeStyle Libre continuous glucose monitoring system continued its strong performance, with global sales reaching $1.4 billion, representing 15% growth year-over-year. This diabetes care franchise remains a key growth driver, with expanding market penetration in both developed and emerging markets.
Research and development expenses totaled $1.8 billion, or 14.3% of sales, maintaining Abbott’s commitment to innovation across its medical technology platforms. The company advanced several pipeline programs, including next-generation cardiac devices and expanded diagnostic testing capabilities.
Market Reaction and Forward Outlook
Abbott’s stock showed minimal movement in after-hours trading, reflecting the mixed nature of the earnings report. The EPS beat provided support, while the revenue miss tempered investor enthusiasm. Trading volume remained within normal ranges as investors digested the quarterly results.
Management maintained its full-year 2026 EPS guidance range of $5.15 to $5.25, suggesting confidence in the company’s ability to deliver consistent earnings growth despite revenue volatility. The company expects continued strength in its diabetes care and diagnostics businesses to offset headwinds in other segments.
Analysts noted Abbott’s resilient business model and diversified revenue streams as key strengths, with several maintaining buy ratings despite the revenue shortfall. The healthcare sector continues to benefit from demographic trends and increasing global healthcare spending, positioning Abbott for long-term growth.
This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.